Fig. 1.
Fig. 1. Significant increase in the percentage of peripheral CD45RA+ T cells in patients with thymoma compared with nonthymoma patients. / (A) Dot-plot displays of 3-color FACS-based analyses of CD69 and CD45RA expression by PBL, gated on CD3+ T cells, in a control versus a thymoma patient (both men, 64 years old). The proportion of circulating CD45RA+CD69− T cells is increased in the thymoma patient compared with the healthy control. (B) The percentage of circulating CD45RA+ T cells in 15 patients with thymoma (▴) is significantly higher than the percentage of circulating CD45RA+ T cells in sex- and age-matched healthy controls (▵; P = .01). (C) There is no significant difference in the percentage of circulating CD45RA+ T cells between 11 MG patients without thymoma but with TFH (♦) and normal sex- and age-matched controls (◊; P = .95).

Significant increase in the percentage of peripheral CD45RA+ T cells in patients with thymoma compared with nonthymoma patients.

(A) Dot-plot displays of 3-color FACS-based analyses of CD69 and CD45RA expression by PBL, gated on CD3+ T cells, in a control versus a thymoma patient (both men, 64 years old). The proportion of circulating CD45RA+CD69− T cells is increased in the thymoma patient compared with the healthy control. (B) The percentage of circulating CD45RA+ T cells in 15 patients with thymoma (▴) is significantly higher than the percentage of circulating CD45RA+ T cells in sex- and age-matched healthy controls (▵; P = .01). (C) There is no significant difference in the percentage of circulating CD45RA+ T cells between 11 MG patients without thymoma but with TFH (♦) and normal sex- and age-matched controls (◊; P = .95).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal